MediGene AG · LS:A40ESG
MediGene — H1 2014 Earnings Presentation
19 slides from MediGene's earnings presentation, Aug 7, 2014
Slide 1: Analyst conference call
Analyst conference call Results for the first 6 months of 2014 7 August 2014 Peter Llewellyn-Davies, CFO
Slide 2: Forward-looking statements
This presentation contains forward-looking statements - that is, statements related to future, not past, events. These statements may be identified either orally or in writing by words as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "will", "may" or words of simila
Slide 3: Activities since beginning of 2014 – Pivotal events
Activities since beginning of 2014 – Pivotal events Transforming acquisition & integration of Trianta Immunotherapies Continued partnering of advanced products €15.9 m secured from capital increase mainly to fund immunotherapy programmes 3
Slide 4: Activities since beginning of 2014 – Immunotherapies
Activities since beginning of 2014 – Immunotherapies DC vaccines: Ongoing investigator-initiated trials US patent relating to the manufacturing of mature dendritic cells granted m4 Award project on the development of optimized DC vaccine formulation successfully completed TCR-modified T cells: Ongoi
Slide 5: Other activities since beginning of 2014 – Marketed drug and development project
Other activities since beginning of 2014 – Marketed drug and development project Worldwide partners: Veregen®: Market launch in 8 European countries and Canada Commercialisation agreement for UK and Ireland AAVLP: Preclinical data from long-term study with Pennsylvania State University Final data un
Slide 6: Other activities since beginning of 2014 – Partnered drug candidates
Other activities since beginning of 2014 – Partnered drug candidates EndoTAG®-1: Preparation of global Phase III study in breast cancer (TNBC) by partner SynCore Biotechnology Co. Ltd. RhuDex®: Licensing agreement signed with Dr. Falk Pharma for RhuDex in hepatology and gastroenterology with initia
Slide 7: Financial Report 6M 2014
medigene Financial Report 6M 2014
Slide 8: Financial overview for the first 6 months of 2014
Financial overview for the first 6 months of 2014 Increase in revenue Total revenue up by 90% to €6.1 m (6M 2013: €3.2 m) Veregen® revenue increased by 36% to €2.6 m (6M 2013: €1.9 m) Reduction of loss EBITDA loss reduced by 62% to €1.6 m (6M 2013: €4.3 m) Net loss reduced by 50% to €2.8 m (6M 2013:
Slide 9: Increase in revenue
Increase in revenue In € m Veregen® in-market sales Total Veregen® revenue Total revenue 6.1 2.6 8.0 7.0 1.9 -13% +36% 3.2 +90% 6M 2013 6M 2014 6M 2013 6M 2014 6M 2013 6M 2014 Revenue (in € k) 6M 2013 6M 2014 Change Veregen® Royalties 1,243 1,018 -18% Product revenue (supply chain) 554 837 51% Miles
Slide 10: Operating expenses within plan
Operating expenses within plan In € m R&D expenses SG&A expenses 3.4 3.4 -1% 3.6 3.9 +8% 6M 2013 6M 2014 6M 2013 6M 2014 R&D expenses: SG&A expenses: Decrease due to lower costs for Higher costs due to Trianta preclinical and clinical trials of acquisition partnered products Continued lower fixed co
Slide 11: Reduction of loss
Reduction of loss In € m EBITDA 6-Months net result -4.3 -1.6 -5.7 -2.8 -62% -50% 6M 2013 6M 2014 6M 2013 6M 2014 Improvement due to increase in total revenue by €2.9 m 11
Slide 12: Financial guidance 2014 confirmed
Financial guidance 2014 confirmed Improvement Actual 2013 Guidance 2014 2014 Double-digit Total revenue €7.6 m 20 - 30% percentage increase Veregen® €4.2 m €5 - 6 m > 20% EBITDA loss €8.3 m €4 - 6 m > 25% Total revenue consists mainly of Revenue Veregen® Increase from R&D funding; grants Non
Slide 13: Funding for immunotherapy platforms through capital measure
Funding for immunotherapy platforms through capital measure Raising of €15.9 m by issuance of 3,016,082 new shares and 818,658 convertible notes Placement of all available new shares close to the current market price (€5.00) without discount Participation of new renowned institutional investors, inc
Slide 14: Capital measure added institutional investors
Capital measure added institutional investors * 4,4% Key share information • Listed on the FSE (Prime Standard) • Shares after capital increase: 13,906,032 • Share price development 6M 2014: +39% • Current market cap of approx. ~ €65 m *Capital increase July 2014 14
Slide 15: Outlook for immunotherapy platforms
Outlook for immunotherapy platforms DC vaccines: Continuation of investigator-initiated trials Initiation of a further clinical study in AML in 2014 Additional clinical study in 2015 TCR-modified T cells Development of GMP-compliant manufacturing process will be continued Preparation of clinical dev
Slide 16: Outlook for marketed & partnered portfolio
Outlook for marketed & partnered portfolio Worldwide partners: Veregen® Growth in in-market sales to continue in double-digit percent range Market authorization applications for further 8 European countries SynCore Biotechnology Ltd.: EndoTAG®-1 Further preparation for start of phase III TNBC trial
Slide 17: medigene
medigene &TRANSFORMAT
Slide 18: Questions & Answers
medigene Questions & Answers
Slide 19: Medigene AG contact details
Medigene AG MediGene AG T +49 - 89 - 20 00 33 - 0 Lochhamer Straße 11 F +49 - 89 - 20 00 33 - 2920 82152 Planegg/Martinsried Planegg / Martinsried investor@medigene.com Germany www.medigene.com Listed on Frankfurt Stock Exchange (MDG1, (MDG, Prime PrimeStandard) Standard)